Once deemed a “functional wasteland,” Y chromosome is found to play a role in cancer immunity The finding may alter biology textbooks

Genetic counseling can improve genetic screening and accelerate clinical trial success

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

David Liu awarded 2025 Breakthrough Prize in Life Sciences

Howard Hughes Medical Institute Investigator David R. Liu was awarded the 2025 Breakthrough Prize in Life Sciences for developing two gene-editing technologies—known as base editing and prime editing—which enable the correction or replacement of virtually any genetic mutation, including those that cause countless human genetic diseases.

April 11, 2025

Vol.51 No.14

In Brief

Eric Green leaves his job as director of the NIH National Human Genome Research Institute

After serving as the director of the National Human Genome Research Institute for more than 15 years, Eric Green has left his role.

March 21, 2025

Vol.51 No.11

Clinical Trials & Tribulations

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy.

Researchers identify HMGA1 as key driver in colon cancer development

A gene called high mobility group A1 may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, Johns Hopkins Department of Medicine, Johns Hopkins Department of Pathology and the Johns Hopkins Institute for Cell Engineering.

February 28, 2025

Vol.51 No.08

Obituary

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.

January 24, 2025

Vol.51 No.03

By Melinda Krigel

Once deemed a “functional wasteland,” Y chromosome is found to play a role in cancer immunity

The finding may alter biology textbooks

YOU MAY BE INTERESTED IN

Genetic counseling can improve genetic screening and accelerate clinical trial success

David Liu awarded 2025 Breakthrough Prize in Life Sciences

Eric Green leaves his job as director of the NIH National Human Genome Research Institute

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

Researchers identify HMGA1 as key driver in colon cancer development

Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48

Renew today!

Subscriber content

Never miss an issue!

Login